Form 4: Beam Therapeutics SVP Sells Shares Under 10b5-1 Plan

Bethany J Cavanagh, SVP of Finance and Treasurer at Beam Therapeutics, sold 6,198 shares of common stock for approximately $35.00 per share under a pre-arranged trading plan.

Summary

• Bethany J Cavanagh, the Senior Vice President of Finance and Treasurer at Beam Therapeutics Inc. (BEAM), reported a sale of common stock.
• The transaction involved the disposition of 6,198 shares of Beam Therapeutics common stock.
• The shares were sold at a weighted average price of $35.0005 per share, with individual transactions ranging from $35.00 to $35.015.
• The sale was executed on January 22, 2026, pursuant to a Rule 10b5-1 trading plan adopted by Ms. Cavanagh on September 19, 2025.
• Following this transaction, Ms. Cavanagh beneficially owns 34,813 shares of Beam Therapeutics common stock directly.

Sentiment

Score: 5

Explanation: The transaction is a routine insider sale executed under a pre-arranged 10b5-1 trading plan, which typically indicates a planned financial management activity rather than a reaction to new company-specific information. This generally results in a neutral market sentiment.

Future Outlook

This Form 4 filing reports a past insider transaction and does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing reports a routine insider stock transaction and does not provide information directly related to broader industry trends or competitor activities. Such transactions are common for executives managing personal finances and diversifying portfolios.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in insider ownership, which is generally not considered significant given it's a pre-planned transaction by an SVP.

Key Dates

Keywords

Beam Therapeutics, BEAM, insider trading, Form 4, stock sale, 10b5-1 plan, executive transaction